Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meningitis - Overview
Meningitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Meningitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meningitis - Companies Involved in Therapeutics Development
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
Eubiologics Co Ltd
FUJIFILM Toyama Chemical Co Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Lineus Bioscience Inc
Matis BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Olymvax Biopharmaceuticals Inc
Pneumagen Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd
Meningitis - Drug Profiles
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSB-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EUC-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flucytosine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A and C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYC-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neumifil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal [serotype 4, 6A] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-2307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1129 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1598 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meningitis - Dormant Projects
Meningitis - Discontinued Products
Meningitis - Product Development Milestones
Featured News & Press Releases
Feb 19, 2020: Matis BioPharma announces DSMB approval to commence part 2 of ECT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Oct 14, 2019: Matis BioPharma initiates ECT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis
Oct 07, 2019: Matis BioPharma receives orphan drug desigtion from U.S. FDA for MAT2203 for the treatment of cryptococcosis
Jul 25, 2019: Matis BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Desigtions From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
Jun 03, 2019: Matis BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitatiol
May 28, 2019: Matis BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Jourl, mBio
May 01, 2019: Matis BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference
Dec 20, 2018: Matis BioPharma to present data on MAT2203 at Biotech Showcase 2019
Aug 08, 2017: Matis BioPharma Reaffirms Clinical and Regulatory Strategy to Advance MAT2203
Jun 02, 2017: Matis BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
May 30, 2017: Matis BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference
Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated
Jun 01, 2016: Viamet Receives Fast Track Desigtion from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis
Sep 16, 2015: FDA Grants QIDP Desigtion to VT-1129 for Treatment of Cryptococcal Meningitis
Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Meningitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Meningitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Meningitis - Pipeline by CanSino Biologics Inc, H1 2020
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
Meningitis - Pipeline by Eubiologics Co Ltd, H1 2020
Meningitis - Pipeline by FUJIFILM Toyama Chemical Co Ltd, H1 2020
Meningitis - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, H1 2020
Meningitis - Pipeline by Linnaeus Bioscience Inc, H1 2020
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H1 2020
Meningitis - Pipeline by Mycovia Pharmaceuticals Inc, H1 2020
Meningitis - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
Meningitis - Pipeline by Pneumagen Ltd, H1 2020
Meningitis - Pipeline by TGV Therapeutics, H1 2020
Meningitis - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
Meningitis - Dormant Projects, H1 2020
Meningitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Meningitis - Discontinued Products, H1 2020